Methods

Study Population
Patients were considered eligible for the study if they had symptomatic heart failure for more than 3 months and they had a left ventricular fractional shortening less than 25%. In addition, study patients had to be clinically stable under the standard therapy of digoxin, diuretics, and angiotensinconverting enzyme inhibitor. The study population consisted of 47 patients (mean age, 54±14 years; 38 men, 9 women). All patients were diagnosed as having DCM according to the criteria of the World Health Organization/International Society and Federation of Cardiology definition of cardiomyopathies. 13 Patients were excluded if they had obstructive lung disease, asthma or symptomatic peripheral vascular disease. All patients participated in the present study after giving informed consent.
Echocardiographic Study
In all patients, M-mode and 2-dimensional echocardiographic studies were performed with an Aloka SSD 870 or SSD 9000 imaging system (Tokyo, Japan) with 2.5-or 3.5-MHz transducers. The M-mode echocardiogram was recorded on a strip-chart recorder at a paper speed of 50 mm/s or 100 mm/s. From the M-mode echocardiographic study, the following conventional variables were measured according to the criteria of the American Society of Echocardiography 14 : left ventricular dimension at end-diastole (LVDd) and end-systole (LVDs). Left ventricular volume was calculated with Teichholtz's formula, and the ejection fraction (EF) was determined. At the time of the echocar- 
Thallium-201 Myocardial Scintigraphy and the Determination of Extent Score
Tl-201 scintigraphy at rest was performed in all patients with DCM, using a method described previously. 15 Briefly, subjects were examined in the morning after an overnight fast. Imaging at rest was begun 10 min after administration of 111 MBq of thallium-201, and the imaging was repeated 5 h later. The single photon emission computed tomography (SPECT) system (GCA 9300; Toshiba, Tokyo, Japan; and Scintipac 2400; Shimadzu, Kyoto, Japan) consisted of a triple-head, digital gamma camera equipped with highresolution, low-energy, parallel-hole collimators. A scintillation camera was rotated for 90 s for each of 36 projections over 360°circular orbits. Energy discrimination was provided by a 15% window centered on the 72 keV photopeak of thallium-201. A series of each 3.5-mm-thick slices was reconstructed with filtered backprojection by a ramp filter. Attenuation correction was made by uniform correction of the Chang method to multiply the original reconstructed image by the correction matrix; 16 scatter correction was also made.
The computerized thallium-201 tomographic method proposed by Garcia et al 17 was used to quantify the size of myocardial perfusion defects. A polar map was formulated by comparing the normalized maximal count value at each point with the normal value at the corresponding point. To depict 2 kinds of extent polar map, we selected 2 kinds of lower normal limits, mean -2SD and mean -3SD. The extent score (ES) was defined as the number of points that fell below the lower normal limits and was expressed as a percentage of the total left ventricular points on the extent polar map. 18 We named these 2 kinds of extent score ES-2 and ES-3, respectively. In order to quantitate the size of mild to moderate myocardial perfusion defects, the ES difference between ES-2 and ES-3 was calculated in each case. Patients were classified according to the degree of ES-2 and ES difference: mild-defect type (mild-type) was defined as one with ES-2 <26% (the basis of the median value of ES-2), moderate-defect type (moderate-type) was defined as one with ES-2 ≥26% and ES difference ≥14% (the basis of the median value of ES difference) and severedefect type (severe-type) was defined as one with ES-2 ≥26% and ES difference <14% (Fig 1) .
Iodine-123-Metaiodobenzylguanidine Myocardial Scintigraphy
MIBG scintigraphy was performed in 41 of the 47 patients. On the day of imaging, patients were instructed not to have breakfast and to continue fasting until the end of the last imaging session. Iodine-123-metaiodobenzylguanidine (111 MBq) was intravenously administered, and myocardial SPECT images were obtained at 15 min (early image) and 5 h (delayed image) after administration. The SPECT system was the same as that used for Tl-201 scintigraphy. Energy discrimination was provided by a 15% window centered on the 160 keV photopeak of iodine-123. A series of each 3.5-mm-thick slices was reconstructed under the same conditions described for Tl-201 scintigraphy. The polar map for MIBG scintigraphy was determined in the same way as for Tl-201 scintigraphy.
For quantitative analysis of the myocardial iodine-123-metaiodobenzylguanidine accumulation, anterior planar projection images were acquired in the SPECT studies. A region of interest (ROI) was selected to encompass the whole heart, and a square ROI, usually 10×10 pixels in size, was selected to include the mediastinum on both the early and delayed images. The counts per pixel were measured for each ROI, and the heart-to-mediastinum (H/M) iodine-123-metaiodobenzylguanidine activity ratio was calculated. The activity of iodine-123-metaiodobenzylguanidine was corrected by time interval and background, and the myocardial washout rate of iodine-123-metaiodobenzylguanidine was determined as the percentage of change in activity from early image to delayed image. The normal range of the myocardial washout rate in our institute was 3-23%. 
Measurement of Plasma Concentrations of Atrial and Brain Natriuretic Peptide
Plasma atrial and brain natriuretic peptide (ANP and BNP) concentrations were determined as reported previously. 19 A blood sample was taken from the antecubital vein in the morning after 30 min of supine rest. Blood was immediately transferred into chilled glass tubes containing disodium EDTA (1 mg/ml) and aprotinin (500 U/ml) and centrifuged at 3,000 rpm for 10 min at 4°C. The plasma was frozen and stored at -80°C until radioimmunoassay (RIA) was performed for measurement of the plasma concentrations of ANP (Shiono RIA assay kit, Shionogi Co, Ltd, Osaka, Japan) and BNP (S-1215, Shionogi Co, Ltd). At our institution, the normal values are <43.0 pg/ml for plasma ANP and <17.0 pg/ml for plasma BNP.
-Blocker Therapy Twenty-two patients were treated with metoprolol, 10 patients were treated with carvedilol and 15 patients were treated with bevantolol. Patients received titrated doses of -blockers beginning with a low value of 2.5 or 5 mg and increasing gradually to the maximal dose determined by one of three end points, which were either a decrease in systolic blood pressure to less than 90 mmHg, a decrease in heart rate (HR) at rest to less than 50 beats/min, or clinical deterioration. Mean maintenance doses were 39±15 mg (from 15 mg to 70 mg) for metoprolol, 13±3 mg (from 10 mg to 20 mg) for carvedilol and 55±25 mg (from 20 mg to 120 mg) for bevantolol. Under the same standard therapy, all patients were treated with -blocker for 6 months.
Echocardiographic studies were performed before and 6 months after treatment. Patients were classified into group A (n=33), if their LVDd decreased by 5 mm or more or the EF improved by 5% or more with -blocker therapy, and group B (n=14), for those whose LVDd change was less than 5 mm and EF change was less than 5%. 20 
Statistical Analysis
Data are presented as mean ± S.D. Baseline characteristics, except for ANP and BNP, were analyzed with an unpaired t test or chi-square test (for nonparametrically distributed values). Between group differences in ANP and BNP were tested by Wilcoxon signed rank test. The relationship between the defect type and response to -blocker therapy was analyzed by chi-square test. Multivariate logistic regression analysis was performed to determine independent predictors of response to -blocker therapy. All calculations were performed on a personal computer with the statistical package StatView (Abacus, Concepts, Inc, Berkeley, CA, USA 1994). A value of p<0.05 was considered significant.
Results
Clinical Characteristics and Natriuretic Peptides of the 2 Groups at Baseline
When clinical characteristics and natriuretic peptides were evaluated at the start of the study, no significant between-group differences were found in age, sex, New York Heart Association (NYHA) functional class, concomitant medications and number of atrial fibrillations (Table 1 ). There were also no significant differences in mean dose of concomitant medications of the 2 groups. And finally, ANP and BNP values did not differ significantly between the 2 groups. Table 2 shows the hemodynamics and cardiac function in the 2 groups. Although there were no significant differences in HR, systolic blood pressure, LVDd and LVDs between the 2 groups at the start of the study, EF was significantly greater in group B than in group A. Table 3 shows Tl-201 and MIBG scintigraphic findings in the 2 groups at the start of the study. Although ES-2 and ES difference were not significantly different between the 2 groups, ES-3 was greater in group B than in group A. Early H/M, delayed H/M and washout rate were not significantly different between the 2 groups.
Hemodynamics, Cardiac Function, and Tl-201 Scintigraphic and MIBG Scintigraphic Findings in the 2 Groups
Relation Between the Defect Type on Tl-201 Scintigraphy and Response to -Blocker
The relation between the defect type on Tl-201 scintigraphy and response to -blocker therapy was examined for the 2 groups at the start of the study. Group 
Logistic Analysis and Probability of Response
Results of multivariate logistic regression analysis to determine independent predictors of response to -blocker therapy are shown in Table 4 . Of all the dependent variables, ES-3, mild-type and severe-type remained statistically significant as independent predictors. Among 41 patients with mild-type or moderate-type, 32 patients responded to -blocker therapy. With the value of mild-type or moderate-type, the defect type showed a sensitivity of 78%, specificity of 83% and accuracy of 79%.
Discussion
In the present study, the defect score and pattern on Tl-201 scintigraphy in patients with DCM were associated with a response to -blocker therapy. In contrast, the parameters established with MIBG scintigraphy showed no significant relation to the response to -blocker therapy.
We previously reported that left ventricular end-systolic wall stress is a potent prognostic variable in patients with DCM, 21 and in that study, left ventricular end-systolic wall stress and ES of Tl-201 scintigraphy were significantly positively correlated. 21 Doi et al 11 and Shiotani et al 12 reported that the severity of Tl-201 perfusion defects in patients with DCM is associated with a poor prognosis. Bukley et al 22 indicated that constant perfusion defects seen on thallium scans in patients with DCM might represent areas of myocardial fibrosis and scarring. Li et al 23 also reported a significant relation between perfusion defect on Tl-201 and myocardial fibrosis.
Yamada et al 24 demonstrated that patients with mild fibrinogenesis on myocardial biopsy responded to -blocker therapy, but those with severe fibrinogenesis did not. They also demonstrated that -blocker therapy would be expected to be more effective in patients in whom the dominant type of fibrosis was interfascicular rather than intercellular. Nishi et al 25 reported that isoproterenol stress echocardiography predicted the response to -blocker therapy in patients with DCM and they speculated that the severely reduced response to isoproterenol might be because of myocardial damage caused by fibrosis or irreversible degeneration. In our study, the defect score and pattern of Tl-201 were associated with the response to -blocker therapy. We think that the area of difference between ES-2 and ES-3 may express the area of mild to moderate myocardial damage. We also think that DCM patients with mild-type or moderate-type are responsive to -blocker therapy and Tl-201 may detect reversible damage of the myocardium. We suggest that DCM patients with the mild to moderate type should be treated with -blocker.
Some investigators 26, 27 reported that a favorable response occurs in patients with a higher heart rate and more advanced left ventricular dysfunction. However, Eichhorn et al 28 and Yamazaki et al 10 reported that EF before the administration of -blocker did not predict the response to therapy. In our data, patients with a lower EF showed a good response to -blocker. Left ventricular variables for predicting the effect of -blocker therapy remain controversial in patients with DCM and the exact mechanisms for this remained to be determined. Despite the lack of significant difference in the values of ANP and BNP, these values were less in group A than in group B, which may be related to the response to -blocker therapy.
MIBG scintigraphy is considered a useful tool for detecting abnormalities of the myocardial adrenergic nervous system in patients with heart failure. 29, 30 Recently some studies noted a potential role for MIBG scintigraphy in predicting therapeutic response to -blocker in patients with heart failure. Suwa et al 8 reported that the H/M ratio on the delayed image is a good predictor of response to -blocker therapy with a threshold of 1.7 (sensitivity = 91%, specificity = 92%). Choi et al 31 reported that the washout rate showed a significant inverse correlation with the increase of ejection fraction in patients treated with -blocker. Fukuoka et al 9 and Yamazaki et al 10 , however, observed no difference between responders and non-responders to -blocker therapy in terms of washout rate and delayed H/M ratio before -blocker therapy. In the present study, there was no significant difference between responders and non-responders to -blocker therapy in washout rate and delayed H/M ratio at the start of the therapy, and MIBG scintigraphy could not predict the response to -blocker therapy in patients with DCM. Approximately half of the patients studied by Suwa et al 8 were in NYHA functional class IV, but most patients in our study were in NYHA II-III and this difference in NYHA functional class may result in the different results for MIBG in redicting the response to -blocker therapy.
Study Limitations
None of the patients was in NYHA functional class IV at the start of this study, thus it is unclear whether the effect of -blocker therapy can be predicted by the defect score and pattern of TL in DCM patients in that functional class. Second, the ES has been established previously, but the definition of defect type is an original idea. However, we think that this method could be distinguish between mild to moderate myocardial perfusion defects and severe myocardial perfusion defects. Third, this study could not investigate the relation between defect type noted on Tl-201 scintigraphy and myocardial pathologic findings. It is not necessarily correct that DCM patients with mild to moderate defect type always have less myocardial fibrosis or less myocardial degeneration. The implication of the present data, however, suggests that the more severe the defect score on Tl-201 scintigraphy, the more extensive the myocardial damage. Further study is required in a larger number of DCM patients with severe heart failure to resolve these questions.
Conclusions
Tl-201 is useful to predict whether patients with DCM will respond to -blocker therapy and those DCM patients with a mild to moderate defect-type on Tl-201 should be positively treated with -blocker.
